Spine BioPharma Inc. announced that it has signed an agreement with Ensol BioSciences Inc. to expand the indications (treatment scope) of its therapeutic drug treatment candidate, SB-01 For Injection. The agreement, valued at a total of $155 million, grants Spine BioPharma the exclusive rights to develop and commercialize SB-01 For Injection, for all additional indications beyond spine-related diseases, such as osteoarthritis, fibrotic diseases, and Oncological indications.